Citation Impact
Citing Papers
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Addition of a Low Fixed Number of CD3 + Cells to CD34-Enriched Allografts: Effects on Engraftment, Graft-versus-Host Disease, and Survival after Related and Unrelated Peripheral Stem Cell Transplantation
2003
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
Bispecific antibodies for cancer therapy
2009
NK Cell Responsiveness Is Tuned Commensurate with the Number of Inhibitory Receptors for Self-MHC Class I: The Rheostat Model
2009
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
2008
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
2008
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Antibody‐targeted superantigen therapy induces tumor‐infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma
1996
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
2004 Standout
Inhibition of RET tyrosine kinase by SU5416
2006
New approaches to antibody therapy
2000
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
2003 Standout
Ranibizumab for Neovascular Age-Related Macular Degeneration
2006 Standout
New insights into nNOS regulation of vascular homeostasis
2005 StandoutNobel
Vascular targeting—a new approach to the therapy of solid tumors
1994
The future of monoclonal antibody engineering
2001
Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning
1996 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Expression of Vascular Endothelial Growth Factor Receptor 1 in Bone Marrow-derived Mesenchymal Cells Is Dependent on Hypoxia-inducible Factor 1
2006 StandoutNobel
Utility of positron emission tomography scans in mantle cell lymphoma
2011
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
CD1d is expressed on B‐chronic lymphocytic leukemia cells and mediates α‐galactosylceramide presentation to natural killer T lymphocytes
2004
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group
2010
Graft-versus-host disease
2009 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Biology and management of relapsed acute myeloid leukaemia
2005
Current treatment standards and future strategies in mantle cell lymphoma
2008
Molecular genetics in acute myeloid leukemia
2010
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
1998 StandoutNature
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
New aspects of natural-killer-cell surveillance and therapy of cancer
2002
Primary brain tumours in adults
2012 Standout
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
2007
Psychological Stress and the Human Immune System: A Meta-Analytic Study of 30 Years of Inquiry.
2004 Standout
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Angiogenesis as a therapeutic target
2005 StandoutNature
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
The management of brain edema in brain tumors
2004
The cancer genome
2009 StandoutNature
The Immunobiology of Cancer Immunosurveillance and Immunoediting
2004 Standout
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
2004 Standout
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8 + T cells in a spectrum of human MHC I haplotypes
2007 StandoutNobel
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients
2006 StandoutNobel
Tyrosine Kinases as Targets for Cancer Therapy
2005
Cytarabine, Ki‐67, and SOX11 in patients with mantle cell lymphoma receiving rituximab‐containing autologous stem cell transplantation during first remission
2013
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
2006
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
2004
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
2004 Standout
Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
2005 Standout
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
2012 StandoutNobel
T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28
1996
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
1998 StandoutScience
Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia Study Group Ulm
2002
Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor
2005 StandoutNobel
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
2001
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
2005
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma
1999 Standout
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
1996
Satellite Cells and the Muscle Stem Cell Niche
2013 Standout
Comparative Analysis of Mutant Tyrosine Kinase Chemical Rescue
2009 StandoutNobel
Antigen-Specific Cytotoxicity by Invariant NKT Cells In Vivo Is CD95/CD178-Dependent and Is Correlated with Antigenic Potency
2010 StandoutNobel
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
2009
Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in hodgkin's disease, the Milan Cancer Institute Experience
2000
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia
2006 Standout
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
1999 StandoutNobel
Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
2000
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of Wolfram Jung being referenced
Self‐tolerance of Human Natural Killer Cells Lacking Self‐HLA‐specific Inhibitory Receptors
2008
The role of lymphocyte subsets and adhesion molecules in T cell‐dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies
1995
The Clinical Significance of Cytokines and Soluble Forms of Membrane-Derived Activation Antigens in the Serum of Patients with Hodgkin's Disease
1992
A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin's cells by unstimulated natural killer cells In AND In vivo
1993
Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody
2000
Increased levels of circulating interleukin‐6 in patients with hodgkin's disease
1991
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia
2002
Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
1990
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
2007
Clinical response following adjuvant Temozolomide in a patient with primary cerebral lymphoma.
2005
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
2003
Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells
1994 Science
Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody
1997